ArticleTherapeutic advances in hematology2026
Individualized decitabine dosing for post-HSCT maintenance in MDS and secondary AML from MDS: long-term outcomes from the PODAC trial and matched controls.
Silvia Park et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.